Skip to main content

Table 2 Comparison of variables between baseline and 6 months after the administration of dapagliflozin

From: Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

 

Baseline

6 months

p value

Clinical characteristics

 Body weight, kg

66.5 (56.8–76.9)

63.9 (56.2–75.6)

< 0.001

 BSA, m2

1.73 (1.57–1.90)

1.72 (1.55–1.88)

< 0.001

 Systolic blood pressure, mmHg

130 ± 16

128 ± 18

0.218

 Heart rate, bpm

71 ± 12

70 ± 11

0.610

 BNP, pg/mL

27.9 (9.0–58.2)

28.9 (9.6–62.9)

0.132

 BUN, mg/dL

14.7 (12.1–19.0)

17.2 (14.2–21.2)

< 0.001

 Creatinine, mg/dL

0.80 ± 0.20

0.86 ± 0.23

< 0.001

 eGFR, mL/min/1.73 m2

70.6 ± 17.0

65.6 ± 15.3

0.001

 HbA1c, %

7.2 ± 0.8

7.0 ± 0.8

0.108

 Hemoglobin, g/dL

13.7 ± 1.7

14.4 ± 1.6

0.020

 Hematocrit, %

41.0 ± 4.7

43.8 ± 4.5

0.002

 Lipid profiles, mg/dL

  Triglycerides

127 (84–185)

116 (82–176)

0.155

  LDL cholesterol

98 (86–118)

106 (89–126)

0.078

  HDL cholesterol

51.5 (45.0–60.2)

52 (42.8–65.0)

0.049

 Uric acid, mg/dL

5.1 (4.4–5.9)

4.7 (4.2–5.7)

0.057

Echocardiographic parameters

 LV end-diastolic volume, mL

74.2 (55.1–104.1)

68.5 (54.8–93.8)

0.270

 LV end-systolic volume, mL

24.7 (17.0–54.5)

20.5 (15.2–57.1)

0.105

 LVEF, %

62.3 (49.3–68.3)

63.6 (55.3–71.0)

0.011

 LVMI, g/m2

75.0 (61.7–92.0)

67.0 (55.0–81.9)

< 0.001

 LAVI, mL/m2

31 (23–45)

26 (21–32)

0.001

 e′, cm/s

6.36 ± 1.73

6.82 ± 1.88

0.031

 E/e′

9.3 (7.7–11.8)

8.5 (6.6–10.7)

0.020

 E, cm/s

58.1 (46.8–70.9)

55.1 (45.3–73.7)

0.682

 A, cm/s

76.1 ± 17.8

75.6 ± 16.8

0.765

 E/A

0.71 (0.6–0.80)

0.70 (0.62–0.81)

0.818

  1. Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
  2. Abbreviation as in Table 1